Aptose Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Net Income	-25.47	-25.43	-51.21	-41.82	-65.35	Upgrade
Depreciation & Amortization	0.02	0.03	0.47	0.53	0.62	Upgrade
Loss (Gain) From Sale of Assets	-	0.08	-	0.02	-	Upgrade
Stock-Based Compensation	0.48	1.06	3.65	5.21	12.95	Upgrade
Other Operating Activities	1.27	-0.23	0.09	-0.02	7.52	Upgrade
Change in Accounts Payable	1.65	-4.79	-0.28	7.61	-0.47	Upgrade
Change in Other Net Operating Assets	0.05	-6.7	2.69	-3.84	1.43	Upgrade
Operating Cash Flow	-21.99	-35.98	-44.59	-32.32	-43.3	Upgrade
Capital Expenditures	-	-0.01	-0.03	-0.02	-0.21	Upgrade
Sale of Property, Plant & Equipment	-	0.02	-	-	-	Upgrade
Investment in Securities	-	-	9.99	30.09	-35	Upgrade
Investing Cash Flow	-	0.02	9.96	30.07	-35.21	Upgrade
Long-Term Debt Issued	18.65	10	-	-	-	Upgrade
Long-Term Debt Repaid	-0.1	-	-	-	-	Upgrade
Net Debt Issued (Repaid)	18.55	10	-	-	-	Upgrade
Issuance of Common Stock	0.83	23.44	6.91	0.12	0.23	Upgrade
Other Financing Activities	-	-0.02	-	-	-	Upgrade
Financing Cash Flow	19.38	33.41	6.91	0.12	0.23	Upgrade
Foreign Exchange Rate Adjustments	-	-	0	-0	0.01	Upgrade
Net Cash Flow	-2.61	-2.55	-27.72	-2.14	-78.28	Upgrade
Free Cash Flow	-21.99	-35.98	-44.62	-32.35	-43.52	Upgrade
Free Cash Flow Per Share	-8.98	-51.48	-198.17	-157.76	-219.81	Upgrade
Levered Free Cash Flow	-12.53	-27.03	-25.82	-16.6	-26.03	Upgrade
Unlevered Free Cash Flow	-12	-26.9	-25.82	-16.6	-26.03	Upgrade
Change in Working Capital	1.71	-11.48	2.41	3.77	0.96	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.